Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
NCT07532408 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2026-06-04
Summary
This study aimed to explore the efficacy and safety of romiplostim N01 in the treatment of relapsed/refractory chemoradiotherapy-induced aplastic anemia
Conditions
- Aplastic Anemia
Interventions
- DRUG
-
Romiplostim N01
Romiplostim N01 20 µg/kg subcutaneously once a week for at least 3 months
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-06-30
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
More Related Trials
-
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NCT06279026 ·Status: RECRUITING ·Phase: NA
-
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT02985333 ·Status: WITHDRAWN ·Phase: PHASE2
-
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
NCT00103272 ·Status: TERMINATED ·Phase: PHASE1
-
RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
NCT00729638 ·Status: COMPLETED ·Phase: PHASE1
-
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
NCT04379817 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
NCT05248633 ·Status: RECRUITING ·Phase: PHASE2
-
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
NCT02406222 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib
NCT02158702 ·Status: UNKNOWN ·Phase: PHASE2
-
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NCT05909826 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment
NCT04423367 ·Status: COMPLETED ·Phase: PHASE2
-
Beta Alethine in Treating Patients With Myeloma
NCT00006466 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
NCT05378971 ·Status: RECRUITING ·Phase: NA
-
Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases
NCT05647512 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)
NCT03242460 ·Status: COMPLETED ·Phase: PHASE2
-
Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
NCT02348528 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01297764 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00963274 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
NCT04155749 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma
NCT01050790 ·Status: COMPLETED ·Phase: NA
-
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
NCT01319422 ·Status: COMPLETED ·Phase: PHASE2
-
Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
NCT01250808 ·Status: AVAILABLE
-
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
NCT03140943 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma
NCT00434161 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06644118 ·Status: RECRUITING ·Phase: PHASE1
-
Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01212952 ·Status: COMPLETED ·Phase: PHASE1/PHASE2